S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
NASDAQ:ZEAL

Zealand Pharma A/S - ZEAL Stock Forecast, Price & News

$16.67
-1.63 (-8.91%)
(As of 08/9/2022 05:13 PM ET)
Add
Compare
Today's Range
$16.62
▼
$17.80
50-Day Range
$11.46
▼
$18.74
52-Week Range
$9.93
▼
$34.30
Volume
6,923 shs
Average Volume
5,419 shs
Market Capitalization
$775.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Zealand Pharma A/S MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
0.16% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.30mentions of Zealand Pharma A/S in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.53) to ($2.45) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.85 out of 5 stars

Medical Sector

1092nd out of 1,098 stocks

Pharmaceutical Preparations Industry

534th out of 536 stocks

See Top Rated MarketRank™ Stocks Here
ZEAL stock logo

About Zealand Pharma A/S (NASDAQ:ZEAL) Stock

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Zealand Pharma A/S Stock Up 0.6 %

Shares of ZEAL Stock traded up $0.10 during mid-day trading on Monday, hitting $18.30. 1,662 shares of the stock traded hands, compared to its average volume of 5,408. The stock has a market cap of $851.44 million, a P/E ratio of -5.06 and a beta of 1.49. The stock's fifty day moving average is $14.76 and its two-hundred day moving average is $14.54. Zealand Pharma A/S has a 52-week low of $9.93 and a 52-week high of $34.30. The company has a debt-to-equity ratio of 0.93, a current ratio of 4.79 and a quick ratio of 4.78.

Zealand Pharma A/S (NASDAQ:ZEAL - Get Rating) last released its quarterly earnings results on Thursday, May 12th. The company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($1.01) by $0.38. The business had revenue of $2.27 million during the quarter, compared to analyst estimates of $9.03 million. Zealand Pharma A/S had a negative net margin of 380.22% and a negative return on equity of 89.90%. During the same period in the prior year, the firm posted ($0.94) earnings per share. Equities analysts predict that Zealand Pharma A/S will post -3.53 EPS for the current year.

Receive ZEAL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zealand Pharma A/S and its competitors with MarketBeat's FREE daily newsletter.

ZEAL Stock News Headlines

August 9, 2022 | americanbankingnews.com
Zealand Pharma A/S (ZEAL) to Release Earnings on Thursday
August 8, 2022 | finance.yahoo.com
Zealand Pharma Announces Voluntary Delisting of American Depositary Shares from the U.S.-Based Nasdaq Global Select Market
July 21, 2022 | finance.yahoo.com
Zealand Pharma AS (ZEAL) Stock Jumps 9.1%: Will It Continue to Soar?
July 11, 2022 | msn.com
Pristine Biologicals inaugurates New Sterile Filtered Serum manufacturing facility in New Zealand’s Dargaville
July 11, 2022 | benzinga.com
MediPharm Labs Enters Into $4.68M Purchase Agreement For The Sale Of Australian Facility
July 5, 2022 | msn.com
New Zealand’s medicines budget to boost R&D-based drugmakers
June 3, 2022 | finance.yahoo.com
Zealand Pharma to Participate in Upcoming Investor Conferences
June 2, 2022 | seekingalpha.com
Dr. David Kendall named Zealand Pharma CMO
June 2, 2022 | finance.yahoo.com
Zealand Pharma Announces Appointment of David M. Kendall, M.D., as Chief Medical Officer
May 31, 2022 | finance.yahoo.com
Zealand Pharma Announces Multiple Presentations at the 82nd Annual American Diabetes Association Scientific Sessions, Including Initial Clinical Data on GLP-1/GLP-2 Dual Agonist Dapiglutide
May 25, 2022 | finance.yahoo.com
Zealand Pharma launches long-term incentive program for Zealand’s Corporate Management and employees for 2022
May 19, 2022 | investing.com
"We Think There is a Good Chance of Broad-label Approval" - Needham & Company Bullish on Zealand Pharma Following Phase 3 Data
May 19, 2022 | marketwatch.com
Zealand Pharma Shares Rise 16% After Trial Results for Dasiglucagon
May 19, 2022 | markets.businessinsider.com
Why Zealand Pharma Shares Are Rising
May 19, 2022 | msn.com
Zealand Pharma's Dasiglucagon Aces Late-Stage Study In Pediatric Patients, Shares Move Higher
May 19, 2022 | seekingalpha.com
Zealand Pharma stock soars 17% as dasiglucagon meets main goal in congenital hyperinsulinism study in infants
May 19, 2022 | finance.yahoo.com
Zealand Pharma Announces Positive Results from Phase 3 Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism (CHI)
May 19, 2022 | finance.yahoo.com
Zealand Pharma to seek FDA approval of its treatment for rare genetic disorder in babies
May 17, 2022 | seekingalpha.com
MannKind to acquire insulin delivery device V-Go from Zealand Pharma to bolster diabetes portfolio
May 17, 2022 | nasdaq.com
MannKind Corp. To Acquire V-Go From Zealand Pharma - Quick Facts
May 17, 2022 | marketwatch.com
MannKind Buys V-Go Insulin Device From Zealand Pharma For $10M, Milestones
May 17, 2022 | finance.yahoo.com
MannKind Corporation Announces Agreement to Acquire V-Go® Insulin Delivery Device From Zealand Pharma
May 17, 2022 | finance.yahoo.com
Zealand Pharma Announces Asset Purchase Agreement with MannKind Corporation for V-Go® Insulin Delivery Device
May 12, 2022 | seekingalpha.com
Zealand Pharma A/S (ZEAL) CEO Adam Steensberg on Q1 2022 Earnings Call Transcript
May 12, 2022 | finance.yahoo.com
Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities [CORRECTED]
See More Headlines
Receive ZEAL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zealand Pharma A/S and its competitors with MarketBeat's FREE daily newsletter.

ZEAL Company Calendar

Last Earnings
5/12/2022
Today
8/09/2022
Next Earnings (Confirmed)
8/11/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ZEAL
CUSIP
N/A
CIK
1674988
Web
www.zealandpharma.com
Phone
(458) 877-3600
Fax
45-8877-3898
Employees
355
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($3.62)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-161,990,000.00
Net Margins
-380.22%
Pretax Margin
-364.34%
Return on Equity
-89.90%
Return on Assets
-50.80%

Debt

Debt-to-Equity Ratio
0.93
Current Ratio
4.79
Quick Ratio
4.78

Sales & Book Value

Annual Sales
$46.54 million
Price / Sales
16.67
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.38 per share
Price / Book
4.93

Miscellaneous

Outstanding Shares
46,527,000
Free Float
N/A
Market Cap
$775.61 million
Optionable
Not Optionable
Beta
1.49

Key Executives

  • Mr. Adam Sinding Steensberg M.D. (Age 48)
    Pres & CEO
    Comp: $700.28k
  • Mr. Matthew Donald Dallas (Age 47)
    Sr. VP & CFO
    Comp: $564.06k
  • Mr. Ivan Mourits Moller (Age 50)
    Chief Operating Officer
  • Lani Pollworth Morvan
    Investor Relations & Communications Officer
  • Mr. Mads Kronborg
    Head of Investor Relations & Communication
  • Mr. Ravinder Chahil
    Sr. VP & Gen. Counsel
  • Ms. Christina Sonnenborg Bredal (Age 37)
    Sr. VP and Global Head of People & Organization
  • Ms. Hanne Heidenheim Bak (Age 69)
    Sr. Project Director, R&D Operations Mang. and Employee Representative Director
  • Dr. Jens Damsgaard Mikkelsen M.D.
    Head of Molecular Pharmacology
  • Dr. Danilo Verge
    Head of Global Medical Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ZEAL Stock - Frequently Asked Questions

Should I buy or sell Zealand Pharma A/S stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zealand Pharma A/S in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ZEAL shares.
View ZEAL analyst ratings or view top-rated stocks.

How has Zealand Pharma A/S's stock price performed in 2022?

Zealand Pharma A/S's stock was trading at $21.34 at the start of the year. Since then, ZEAL shares have decreased by 21.8% and is now trading at $16.68.
View the best growth stocks for 2022 here.

When is Zealand Pharma A/S's next earnings date?

Zealand Pharma A/S is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our ZEAL earnings forecast.

How can I listen to Zealand Pharma A/S's earnings call?

Zealand Pharma A/S will be holding an earnings conference call on Thursday, August 11th at 10:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Zealand Pharma A/S's earnings last quarter?

Zealand Pharma A/S (NASDAQ:ZEAL) released its earnings results on Thursday, May, 12th. The company reported ($0.63) earnings per share for the quarter, topping analysts' consensus estimates of ($1.01) by $0.38. The firm had revenue of $2.27 million for the quarter, compared to analyst estimates of $9.03 million. Zealand Pharma A/S had a negative trailing twelve-month return on equity of 89.90% and a negative net margin of 380.22%. During the same period in the prior year, the company posted ($0.94) earnings per share.

What other stocks do shareholders of Zealand Pharma A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zealand Pharma A/S investors own include AbbVie (ABBV), Galapagos (GLPG), Verizon Communications (VZ), Dynavax Technologies (DVAX), EyePoint Pharmaceuticals (EYPT), Progenics Pharmaceuticals (PGNX), Protalix BioTherapeutics (PLX), Portola Pharmaceuticals (PTLA), Sangamo Therapeutics (SGMO) and Sorrento Therapeutics (SRNE).

When did Zealand Pharma A/S IPO?

(ZEAL) raised $75 million in an initial public offering (IPO) on Wednesday, August 9th 2017. The company issued 3,900,000 shares at a price of $19.30 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

What is Zealand Pharma A/S's stock symbol?

Zealand Pharma A/S trades on the NASDAQ under the ticker symbol "ZEAL."

How do I buy shares of Zealand Pharma A/S?

Shares of ZEAL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zealand Pharma A/S's stock price today?

One share of ZEAL stock can currently be purchased for approximately $16.68.

How much money does Zealand Pharma A/S make?

Zealand Pharma A/S (NASDAQ:ZEAL) has a market capitalization of $776.12 million and generates $46.54 million in revenue each year. The company earns $-161,990,000.00 in net income (profit) each year or ($3.62) on an earnings per share basis.

How many employees does Zealand Pharma A/S have?

Zealand Pharma A/S employs 355 workers across the globe.

How can I contact Zealand Pharma A/S?

Zealand Pharma A/S's mailing address is SYDMARKEN 11, COPENHAGEN G7, 2860. The official website for the company is www.zealandpharma.com. The company can be reached via phone at (458) 877-3600, via email at investors@zealandpharma.com, or via fax at 45-8877-3898.

This page (NASDAQ:ZEAL) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.